Stromal Tumours of the Stomach

Downs‐Kelly, Erinn; Rubin, Brian P.; Goldblum, John R.

doi:10.1002/9781118399668.ch14

Cited by 1 publication

(1 citation statement)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myofibroblasts are spindle-shaped cells transiently found in early to mid-phase wound tissue (Werner et al 2007 ). In addition, they are present in abundance in most solid tumours (Downs-Kelly et al 2013 ; Nagarajan et al 2013 ; Yeung et al 2013 ; Yoshida et al 2013 ). Myofibroblasts have also been shown to promote invasiveness in breast carcinoma and pancreatic carcinoma (Dabiri et al 2013 ; Hu et al 2008 ; Mareel et al 2009 ).…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1

2016

View full text Add to dashboard Cite

Glucose deprivation, hypoxia and acidosis are characteristic features of the central core of most solid tumours. Myofibroblasts are stromal cells present in many such solid tumours, including those of the colon, and are known to be involved in all stages of tumour progression. HMGB1 is a nuclear protein with an important role in nucleosome stabilisation and gene transcription; it is also released from immune cells and is involved in the inflammatory process. We report that the microenvironmental condition of glucose deprivation is responsible for the active release of HMGB1 from various types of cancer cell lines (HT-29, MCF-7 and A549) under normoxic conditions. Recombinant HMGB1 (10 ng/ml) triggered proliferation in myofibroblast cells via activation of PI3K and MEK1/2. Conditioned medium collected from glucose-deprived HT-29 colon cancer cells stimulated the migration and invasion of colonic myofibroblasts, and these processes were significantly inhibited by immunoneutralising antibodies to HMGB1, RAGE and TLR4, together with specific inhibitors of PI3K and MEK1/2. Our data suggest that HMGB1 released from cancer cells under glucose deprivation is involved in stimulating colonic myofibroblast migration and invasion and that this occurs through the activation of RAGE and TLR4, resulting in the activation of the MAPK and PI3K signalling pathways. Thus, HMGB1 might be released by cancer cells in areas of low glucose in solid tumours with the resulting activation of myofibroblasts and is a potential therapeutic target to inhibit solid tumour growth.

show abstract